arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Perspective Therapeutics, Inc.

CATX
$3.00 ▲ +0.03 (+1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Perspective Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $221.4M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -54.0%
FCF / Share $-1.29
Trailing P/E
Price / Book 1.1x
FCF Yield
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.43M
Net Income Profit after all expenses
$-103.12M
↓ -30.1%
Operating Margin Operating profit as % of sales
-68.5%
↓ -99.7%
FCF / Share Free cash flow per share
$-1.29
↓ -14.3%
Long-Term Debt Long-term obligations
$1.62M
↓ -3.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Financial Health
94
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 63 quarters